CEPI

CEPI
Name	Coalition for Epidemic Preparedness Innovations
Formation	2017
Type	Public-private partnership
Headquarters	Oslo, Norway; London, United Kingdom
Region served	Global
Leaders	Richard Hatchett (CEO)

CEPI is an international public-private partnership formed to accelerate the development of vaccines against emerging infectious diseases and to strengthen epidemic preparedness. It coordinates funding, scientific strategy, and manufacturing scale-up across a network of research institutions, biotechnology firms, philanthropic organizations, and national agencies. CEPI's activities intersect with global health initiatives, regulatory authorities, and outbreak response mechanisms to shorten timelines from pathogen discovery to vaccine availability.

History

CEPI was announced at the Davos meeting in January 2017 and formally established following consultations with stakeholders such as the Wellcome Trust, the Bill & Melinda Gates Foundation, and the governments of Norway and the United Kingdom. Its founding was influenced by lessons from the 2014–2016 Ebola epidemic and the subsequent formation of the World Health Organization's Research and Development Blueprint. Early partners included the founding donors and vaccine developers that had worked on countermeasures for MERS-CoV, Lassa fever, and Zika virus outbreaks. During the COVID-19 pandemic, CEPI co-led efforts with entities such as Gavi, the Vaccine Alliance and World Health Organization in initiatives to accelerate vaccine candidates and support equitable access. Post-pandemic evaluations drew on inquiries by bodies including the Independent Panel for Pandemic Preparedness and Response and national commissions in United States and United Kingdom.

Organization and Governance

CEPI is governed by a board composed of representatives from donor governments, philanthropic organizations, scientific experts, and industry figures, operating alongside an executive leadership team based in Oslo and London. Its governance framework references standards from institutions like the World Bank and aligns with regulatory guidance from agencies such as the European Medicines Agency and the U.S. Food and Drug Administration. Advisory groups include panels of experts from academic centers including Harvard University, Imperial College London, and the London School of Hygiene & Tropical Medicine, as well as representatives from vaccine manufacturers such as Moderna, Inc., AstraZeneca, and GlaxoSmithKline. CEPI's decision-making balances strategic priorities set by the board with technical recommendations from scientific advisory committees and ethical review boards influenced by frameworks from the Nuffield Council on Bioethics.

Mission and Programs

CEPI's stated mission emphasizes rapid development of safe, effective, and accessible vaccines against priority pathogens identified by the World Health Organization's R&D Blueprint and other threat assessments. Programs target platform technologies such as messenger RNA, viral vectors, and recombinant protein systems used by developers including BioNTech, Johnson & Johnson, and Novavax. CEPI funds prototype pathogen approaches, enabling preemptive development for viral families exemplified by Coronaviridae, Filoviridae, and Arenaviridae. Initiatives also support manufacturing readiness, clinical trial networks linked to institutions like London School of Hygiene & Tropical Medicine and National Institutes of Health, and regulatory preparedness aligned with agencies such as the Medicines and Healthcare products Regulatory Agency.

Funding and Partnerships

CEPI's financial model combines contributions from sovereign donors, foundations, and private-sector partners. Major funders have included Norway, Japan, Germany, India, the Bill & Melinda Gates Foundation, and philanthropic entities comparable to the Wellcome Trust. Partnerships extend to multinational organizations like Gavi, the Vaccine Alliance, WHO, and industry consortia involving companies such as CureVac and Sanofi. CEPI also collaborates with academic consortia at institutions like Johns Hopkins University and Oxford University to coordinate trials and policy engagement. Funding agreements often specify provisions for equitable access and intellectual property arrangements influenced by precedents set in agreements involving UNICEF procurement and Global Fund purchasing mechanisms.

Research and Development Activities

CEPI supports a portfolio of vaccine candidates spanning preclinical discovery, phase 1–3 clinical trials, and manufacturing scale-up. It has invested in platform development, distributed antigen libraries, and standardized assays with reference laboratories including those at Centers for Disease Control and Prevention and Pasteur Institute. Workstreams include challenge studies, correlates of protection research with collaborators such as National Institute of Allergy and Infectious Diseases, and cold-chain innovation with logistics partners experienced by Médecins Sans Frontières. CEPI also underwrites manufacturing surge capacity, technology transfer consortia, and regulatory science projects designed to accelerate emergency use authorizations through engagement with bodies like the European Commission and national competent authorities.

Impact and Criticism

CEPI has been credited with shortening vaccine timelines, catalyzing platform investments, and coordinating multi-sectoral responses during events like the COVID-19 pandemic and regional outbreaks of Lassa fever. Its role in enabling rapid candidate progression attracted praise from global health leaders associated with Gavi, the Vaccine Alliance and the World Health Organization. Criticisms have focused on issues of equitable access, intellectual property stewardship, and the balance between investing in platform technologies versus regionally targeted capacity building. Evaluations by panels including the Independent Panel for Pandemic Preparedness and Response and civil society groups such as Oxfam have urged greater transparency, stronger commitments to manufacturing in low- and middle-income countries, and clearer mechanisms for allocation during scarce supply. Ongoing policy debates reference similar controversies encountered by entities like COVAX and national procurement efforts led by Operation Warp Speed.

Category:Global health organizations